SCHEMBL22147753

SCHEMBL22147753

C[C@@]1(c2ccccc2)CCN(Cc2ccccc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
HSD11B1 P28845 1/20 0.50
ELANE P08246 3/20 0.47
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
MMP1 P03956 1/20 0.47
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
CYP2C19 P33261 3/20 0.45
POLB P06746 2/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
OPRL1 P41146 3/20 0.45
OPRM1 P35372 2/20 0.45
GAA P10253 1/20 0.44
RIPK1 Q13546 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ADAM17 P78536 1/20 0.42
CTSG P08311 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22147836 0.85 SIGMAR1 (0.50) KMT2AMEN1OPRL1OPRM1L3MBTL1
SCHEMBL24992399 0.82 KMT2A (0.61) KMT2AMEN1HSD11B1ELANEDDB1
SCHEMBL31374300 0.80 MMP1 (0.41) KMT2AMEN1HSD11B1MMP2MMP9
SCHEMBL31374298 0.80 MMP1 (0.41) KMT2AMEN1HSD11B1MMP2MMP9
SCHEMBL13201398 0.79 KMT2A (0.58) KMT2AMEN1HSD11B1ELANEDDB1
SCHEMBL29137409 0.79 KMT2A (0.58) KMT2AMEN1HSD11B1ELANEDDB1
SCHEMBL6730533 0.78 KMT2A (0.56) KMT2AMEN1HSD11B1ELANEDDB1
SCHEMBL17184863 0.77 KMT2A (0.46) KMT2AMEN1HSD11B1ELANEDDB1
SCHEMBL3194202 0.77 KMT2A (0.55) KMT2AMEN1HSD11B1ELANEDDB1
SCHEMBL6627912 0.77 MMP2 (0.59) HSD11B1MMP2MMP9MMP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213081-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-07-07 US disclosed
US-20220119377-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-04-21 US disclosed
US-11214568-B2 Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-01-04 US disclosed
EP-3699173-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME California Institute of Technology (US) 2020-08-26 EP disclosed
US-20200199114-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2020-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213081-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME GMNN, GRIA1, GRIA2 KMT2A 1092/4885MEN1 1769/4885HSD11B1 2236/4885
US-20200199114-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME GMNN, GRIA1, GRIA2 KMT2A 1092/4885MEN1 1769/4885HSD11B1 2236/4885
US-20220119377-A1 GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME GMNN, GRIA1, GRIA2 KMT2A 1092/4885MEN1 1769/4885HSD11B1 2236/4885
US-11214568-B2 Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same GMNN, GRIA1, GRIA2 KMT2A 1092/4885MEN1 1769/4885HSD11B1 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.